TY - JOUR AU - Dashtipour, Khashayar AU - Wietek, Stefan AU - Rubin, Bruce AU - Maisonobe, Pascal AU - Bahroo, Laxman AU - Trosch, Richard PY - 2020 DA - 2020/08/31 TI - AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles JO - Journal of Clinical Movement Disorders SP - 8 VL - 7 IS - 1 AB - Cervical dystonia (CD), the most common focal dystonia, is a chronic neurological movement disorder characterized by sustained involuntary contractions of the neck muscles, leading to abnormal postures. AbobotulinumtoxinA (aboBoNT-A) was approved in the US initially as a 500 U per 1-mL dilution and subsequently, as a 500 U/2-mL dilution (or 250 U/mL), thereby providing clinicians with more flexible dosing options to better meet individual patient needs. The objective of this open-label extension study was to evaluate the longer term safety and efficacy of repeat treatments with aboBoNT-A using 2-mL dilutions in adults with cervical dystonia. SN - 2054-7072 UR - https://doi.org/10.1186/s40734-020-00090-x DO - 10.1186/s40734-020-00090-x ID - Dashtipour2020 ER -